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The nonalcoholic steatohepatitis (NASH) drug development graveyard: established 
hurdles and planning for future success
Joost P.H. Drentha and Jörn M. Schattenberg b,c
aDepartment of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands; bDepartment of Medicine, 
University Medical Centre of the Johannes Gutenberg-University, Mainz, Germany; cMetabolic Liver Research Program, University Medical Centre of 
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ABSTRACT
Introduction: Numerous pharmacological compounds that target the different molecular targets 
involved in the pathobiology of nonalcoholic steatohepatitis (NASH) are currently in clinical testing. 
So far, there are no regulatory approvals.
Areas covered: This paper sheds light on the molecular pathways involved in NASH and the drugs 
targeting these pathways. We have identified 10 compounds whose clinical development program has 
been halted. Moreover, we explore early phase clinical trials and dissect the reasons for termination of 
development.
Expert opinion: The main goal of NASH pharmacotherapy is to halt or reverse hepatic fibrosis or to 
achieve the resolution of steatohepatitis. There is an intense competition to develop compounds with 
disease-modulating properties with a focus on anti-metabolic, anti-inflammatory or anti-fibrotic proper-
ties. Numerous study programs, even in late-phase trials, have been halted because of lack of efficacy, 
safety concerns or drug-drug interactions. This underscores the urgent need to provide robust pre-
clinical data and an extensive clinical trial program that builds on reliable data generated in earlier 
stages of clinical development before moving into late stage development.
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1. What is NASH?
Nonalcoholic fatty liver disease (NAFLD) encompasses 
a range of conditions that share the central lesion of excess 
fat, steatosis, in the liver. NAFLD is a leading cause of 
chronic liver disease and recent estimates suggest that the 
prevalence of NAFLD has doubled over the last decade to 
rates beyond 25%. Population-based studies suggest that 
about 25% of NAFLD patients will get steatohepatitis with 
a high risk of fibrosis and cirrhosis denoted as nonalcoholic 
steatohepatitis (NASH) [1]. NASH is often seen as part of 
a complex of other disorders such as hypertension, dyslipi-
demia, obesity, and insulin resistance. In the academic dis-
cussion, the term metabolic associated fatty liver disease 
(MAFLD) has been coined to reflect the complexity of the 
pathobiology. In view of the high prevalence, the burden of 
NASH as a chronic liver disease has risen considerably and, 
it is estimated that by 2025, almost 43 million adults in the 
United States will have developed NASH-related liver dis-
ease [2]. The global NASH market has been valued at USD 
2.94 billion in 2019 and is projected to reach USD 54 billion 
by 2027, growing at a compound annual growth rate of 
58.6% from 2020 to 2027 [3]. Lifestyle modifications with 
regular exercise and a focus on healthy eating habits come 
first in the management of NASH. However, lifestyle mod-
ifications are often not achieved or sustained for prolonged 
period of time. Even more importantly, not all patients with 
NASH respond to weight loss with improvement of their 
liver disease. Thus, treatments that can reverse NASH and 
halt or reverse fibrosis are a major focus of current drug 
development. The road to marketing authorization leads via 
a number of clinical trials that test these compounds 
against a number of primary and secondary endpoints. 
Compound development in NASH as an indication has pro-
ven rather treacherous and the list of compounds that have 
failed to make it to marketing authorization has become 
significant. This paper summarizes the key concepts of phar-
macotherapy in NASH, target identification and discusses 
the reasons for failure for 10 notable drug compounds.
2. Pathogenic drivers of disease progression and 
mortality in NASH
The pathological spectrum encompasses simple steatosis, 
nonalcoholic steatohepatitis (NASH) and pericellular fibrosis 
that can slowly lead to cirrhosis. Lobular inflammation and 
hepatocellular injury are hallmarks of NASH in adjunction 
with varying degrees of fibrosis [4]. NASH is strongly asso-
ciated with visceral adiposity and metabolic inflammation 
[5] and its important consequence hyperinsulinemia, athero-
genic dyslipidemia and arterial hypertension in particular in 
advanced fibrosis. Thus, NASH is more closely related to 
‘metabolic obesity’ than to body weight [6]. Risk factors 
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for NASH include excessive intake of calorie-dense food, 
reduced physical activity and exercise, and genetic suscept-
ibility [7].
A number of pathomechanistic drivers have been identi-
fied and include increased susceptibility to pro-oxidant and 
endotoxin-induced injury, facilitated by increased intestinal 
permeability and intestinal ‘dysbiosis’. Genetic loci involved 
in lipid remodeling in lipid droplets, hepatic very low-density 
lipoprotein secretion and de novo lipogenesis are established 
risk factors for development of the liver-related morbidity in 
NASH [8]. Available data supports lipotoxic mechanisms with 
release of danger activated molecular patterns (DAMPs) and 
activation of innate immunity [9] that contribute to disease 
progression. The network of the above interactive factors 
highlights the complexity of the disease that is influenced 
by extrinsic (e.g. nutrition) and internal (e.g. genetic) factors 
rather than a redundant pathogenic pathway in all patients 
[10]. Importantly, the disease course follows a variable, non- 
linear pattern with phases of progression, non-progression 
and regression along the spectrum toward end-stage liver 
disease, often over several decades [11]. The main causes of 
mortality in patients with NASH are cardiovascular disease 
and cancers, but the risk of hepatic mortality increases stee-
ply with fibrosis stages F3 and F4 [12–14]. Another formid-
able hurdle is the lack of an animal model that faithfully 
replicates the pathophysiology and disease progression of 
NASH. The best existing models can do, is to mimic certain 
aspects of human NASH and this may serve to answer 
focused research questions [13].
3. What are the therapeutic targets?
The prospect of pharmaceutical management of NASH is at 
the horizon and numerous efforts are underway to open up 
the field.
3.1. Nuclear receptor-targeting drugs
Several drugs targeting nuclear receptors have been brought 
forward, and agonists for the farnesoid X receptor (FXR) and 
the peroxisome proliferator-activated receptors (PPARs) are in 
development. The most advanced drug in clinical develop-
ment is the FXR agonist obeticholic acid (OCA). OCA is a semi- 
synthetic analog of the bile acid chenodeoxycholic acid and 
a potent FXR agonist. Its efficacy and safety were reported in 
a phase 3 trial in NASH in a preplanned interim analysis of the 
REGENERATE study [15]. This trial achieved its primary end-
point and demonstrated statistically significant improvement 
in liver fibrosis without worsening of NASH but safety con-
cerns (pruritus, dyslipidemia) were reported. However, the 
authorities did not support accelerated approval and cited 
that the predicted benefit based on a surrogate histopatholo-
gical endpoint remains uncertain and does not sufficiently 
outweigh the safety profile concerns.
3.2. Metabolic hormones and drugs
Steatohepatitis is an important driver of disease progression in 
metabolic-burdened individuals. Therefore, drugs that exert 
beneficial metabolic effects have been previously studied for 
the treatment of NASH. The gut-derived hormone glucagon- 
like peptide-1 (GLP-1) improves insulin secretion, suppresses 
appetite, and delays gastric emptying. Treatment with GLP-1 
analogs improve glycemic control and is also linked to low-
ering of serum ALT levels, suggesting that they have potential 
in NASH treatment. Side effects include nausea, but this 
usually does not lead to drug discontinuation. Resmetirom 
(MGL-3196) is a liver-specific and selective thyroid-β-receptor- 
agonist that was previously explored for its effects on LDL- 
cholesterol and triglycerides. A reduction of intrahepatic fat 
was observed in patients with NASH who received MGL-3196 
[16] and the compound is currently being explored in a phase 
3 trial.
Recently, several members of the fibroblast growth factor 
(FGF) family have been identified as metabolic hormones with 
beneficial effects on NASH. FGF signaling has raised several 
concerns for adverse effects and a short half-life, however the 
availability FGF analogs with improved pharmacokinetic and 
pharmacodynamic profiles have boosted the clinical develop-
ment of this class of drugs [17]. Additionally several inhibitors 
of de-novo hepatic lipogenesis are currently underway, mostly 
in phase 2 clinical trials.
Article highlights
• Current drug development programs in NASH aim to obtain 
conditional approval through analysis of a surrogate marker of 
clinical outcomes after 48 to 72 weeks
• There are at least 10 compounds that have developed for treat-
ment of NASH that went through clinical trial testing and have 
failed to make it to market authorization
• Experimental studies suggest a plethora of possible targets for 
NASH
• There is no evidence that targeting a single pathway will alter the 
natural course of NASH
• Histological evaluation of NASH liver biopsies lacks reliability and 
accuracy and the misclassification of histological lesions threatens 
the statistical power of trials
• It is unclear whether the negative results result from the use of 
ineffective drugs or are due to the fact that the targeted pathways 
are irrelevant for the pathogenesis.
• The lack of validated biomarkers in NASH that predict the devel-
opment of liver-related morbidity and mortality hinder progress in 
drug development
• There is a need for stratification of NASH populations included in 
the registration trials with respect to (liver) disease stage and 
grade but also for presence of comorbidities
• There is a clear disconnect between endpoints required for 
exploratory phase 2 trials and larger, formal, phase 3 studies.
This box summarizes key points contained in the article.
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3.3. Anti-fibrotic drugs
Direct anti-fibrotic medications are currently not available, 
however the inhibition of injury, as the driver of fibrosis in 
liver disease, can lead to fibrosis reversal. Since fibrosis is 
linked to clinical outcomes including overall mortality, pivotal 
trials are frequently assessing fibrosis resolution as the primary 
endpoint. While a pure anti-fibrotic compound is unlikely to 
benefit patients with fibrotic NASH, the combination of a drug 
with predominant effect on fibrosis could benefit patients who 
simultaneously receive modifiers of metabolism. Such combi-
nation would stabilize fibrosis formation while targeting the 
metabolic pathway would inhibit fibrogenesis. Combinations 
with the CCR2/CCR5 agonist cenicriviroc [18] are currently 
explored under this strategy.
4. Halted drug development for NASH (see Table 1)
The path to market authorization for novel compounds that 
ameliorate the (liver-specific) detrimental effects of NASH 
serves to fuel the evidence base using a series of rigorous 
clinical trials. Experiments that have manipulated these targets 
have resulted in a crop of novel engineered specific com-
pounds that come with the promise that targets engagement 
translates in clinical improvement of NASH. In view of the 
multiple targets that may be involved in NASH, the number 
of compounds currently in development is large. Numerous 
compounds have failed to make it through to clinical devel-
opment. We will discuss compounds specifically designed to 
treat NASH that failed after 2016. See Table 1.
4.1. Selonsertib
The selective ASK1 inhibitor, selonsertib, has been trialed in 
two randomized, double-blind, placebo-controlled studies 
[19,20]. Both phase 3 trials evaluated the safety and anti- 
fibrotic efficacy of the drug in approximately 1700 advanced 
NASH patients. STELLAR-3 trial examined patients with brid-
ging fibrosis and STELLAR-4 trial with compensated cirrhosis. 
Patients were randomly assigned to groups receiving 6 mg or 
18 mg of selonsertib or placebo daily for 48 weeks, with paired 
liver biopsies performed at baseline and at the end of the 
trials. The investigators detected a dose-dependent reduction 
hepatic phospho-p38 expression compatible with ASK1 target-
ing but both trials failed to reach the primary efficacy end-
point of fibrosis improvement without worsening of NASH at 
week 48. Adverse events were similar between groups [21].
4.2. Simtuzumab
Simtuzumab, is a humanized monoclonal antibody directed 
against LOXL2, binds to and inhibits LOXL2 enzymatic activity 
and has been investigated because of the potential to prevent 
or reverse fibrosis progression. The phase 2 program consisted 
of two separate multi-center studies and included one study 
of 219 patients with bridging fibrosis and one study of 258 
patients with compensated cirrhosis. Each study consisted of 
three arms with proportional cohorts of simtuzumab or pla-
cebo [22]. Simuzumab was dose orally 75 mg and 125 mg in 
patients with bridging fibrosis, while simtuzumab was given 
intravenously every other week (200 or 700 mg) to compen-
sated cirrhotics. The planned duration of the trial was 
240 weeks but both studies were terminated early and data 
from 197 patients from both trials were assessed at 48 weeks 
and 96 weeks. Endpoints differed per trial. In patients with 
bridging fibrosis, the primary end point was changed from 
baseline to week 96 in hepatic collagen content, as measured 
by morphometry of liver specimens, for patients with cirrhosis, 
the primary end point was changed in hepatic venous pres-
sure gradient from baseline to week 96. Interestingly, all three 
treatment arms of patients with bridging fibrosis had signifi-
cant decreases in hepatic collagen content, but there was no 
statistically significant difference in decrease between simtu-
zumab arms and the placebo arm. The results were unaffected 
after adjusting for diabetes status, weight loss and baseline 
serum lysyl oxidase like two levels. In cirrhotics, both dosages 
of simtuzumab did not change hepatic venous pressure gra-
dient compared to placebo.
4.3. Solithromycin (CEM-101)
Solithromycin (CEM-101) is a first in class CCL24 neutralizing 
antibody. CCL24 plays a significant role in the development of 
Table 1. Drugs that have been (temporarily) withdrawn from seeking marketing authorization for NASH.
Company Drug Drug class Phase Reason
Date of announcement of 
discontinuation
Gilead Selonsertib ASK1 inhibitor 3 Lack of efficacy 2/11/2016
Gilead Simtuzumab LOXL2 neutralizing antibody 2 Lack of efficacy 2/11/2016
Cempra Solithromycin CCL24 neutralizing antibody 1 Hepatotoxicity 28/2/2017
Astra Zeneca AZD4076 (RG-125) Anti micro RNA-103/107 1/2a Unclear 12/6/2017
Gilead Firsocostat 
(monotherapy)
Acetyl-CoA carboxylase (ACC1/ACC2) inhibitor 3 Efficacy 16/12/2019*
Gilead Cilofexor 
(monotherapy)
Farnesoid X receptor agonist 3 Efficacy 16/12/2019*
Boehringer 
Ingelheim





Conatus Emricasan Pan-caspase inhibitor 2b Efficacy 24/6/2019
Genfit Elafibranor PPAR-α/δ agonist 3 Efficacy 23/7/2020
TaiwanJ 
Pharmaceuticals
JKB-121 Toll-like receptor 4 antagonist 2 Efficacy 19/4/2018
Temporary halt
* A future phase 3 clinical trial with combination of these two compounds – without selonsertib is in current development. 
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hepatic fibrosis and liver damage. CCL24, as well as its recep-
tor CCR3, are overexpressed in liver and peripheral blood cells 
of NASH patients. This led to the concept that its blockade 
using a monoclonal antibody such as Solithromycin can be 
utilized as an antifibrotic agent in liver diseases [23]. Cempra 
initiated a phase 2 open-label study (NCT02510599) evaluating 
the effects of solithromycin (200 mg daily for 1 week, followed 
by 200 mg three times a week for 12 weeks) in 15 NASH 
patients (NAS score > 4, presence of fibrosis without cirrhosis) 
on hepatic histology and biomarkers in NASH. Reportedly, 6 
NASH patients had reductions in NAS (mean reduction 1.3) 
and ALAT level (mean reduction, 17.8 U/L) after 90 days of 
treatment with solithromycin. AST was reduced in 5/6 patients 
and unchanged in 1 patient (mean reduction for the six 
patients, 10.1 U/L) [24]. This was accompanied by reductions 
in ballooning hepatocyte degeneration and inflammation. An 
FDA report later suggested that solithromycin carried 
a hepatic injury signature with significant ALAT elevations 
(>3 upper limit of normal (ULN)) in 4/10 patients from the 
phase 1–2 program [25]. In February 2017 the company 
announced that it suspended the development of solithromy-
cin for the treatment of NASH due to ‘unclear’ efficacy [26].
4.4. AZD4076 (RG-125)
Inhibition of micro RNA (miR)-103/107 improves insulin sensitiv-
ity and glucose homeostasis in diet-induced obese rodent mod-
els. Screening of anti-miR-103/107 oligonucleotides (anti-miRs) 
led to the identification of RG-125, an N-acetylgalactosamine – 
conjugated anti-miR. RG-125 induces dose-dependent reduc-
tions in weekly fasting blood glucose and plasma insulin in 
experimental mice models, with significant improvements in 
the homeostatic assessment of insulin resistance through miR- 
103/107 targeting. These data fueled the clinical development by 
Regulus Therapeutics Inc. of RG-125 as a novel insulin sensitizer 
for treatment of type 2 diabetes and metabolic disorders [27]. 
AstraZeneca selected RG-125/AZD4076 in 2015 for development 
under a strategic alliance. In the third quarter of 2016, 
AstraZeneca launched a Phase 1/2a, randomized, single-blind, 
placebo-controlled, multiple ascending dose study in NAFLD 
patients with concomitant type 2 diabetes mellitus. 
(NCT02826525). The study planned to include up to 46 patients 
with type 2 diabetes mellitus (HbA1c 7–11%) and NAFLD (liver fat 
content ≥ 8%) on metformin monotherapy. The primary objec-
tives of this clinical trial were to investigate the safety and toler-
ability of AZD4076 but in December 2017 Regulus Therapeutics 
acknowledged that the clinical development of AZD4076 (RG- 
125) was halted by AstraZeneca.
4.5. Firsocostat
Firsocostat (GS-0976) is a liver-directed allosteric acetyl-CoA 
carboxylase (ACC1/ACC2) inhibitor that blocks de novo lipo-
genesis in hepatocytes [28]. ACC is an attractive pathway as 
this is associated with accumulation of liver fat and subse-
quent lipotoxicity as well as able activation of hepatic stellate 
cells and subsequent liver fibrosis. In phase 2a clinical trial 
targeting 10 NASH patients, a 12 week treatment with 
firsocostat caused significant reductions of hepatic de novo 
lipogenesis [29]. At week 12, 7 patients (70%) had a ≥ 30% 
decrease in magnetic resonance imaging proton density fat 
fraction (MIR-PDFF), a measure that has been shown to trans-
late into histological improvements. Liver stiffness by mag-
netic resonance elastography (MRE) decreased from 3.4 kPa 
at baseline to 3.1 kPa after 12 week fircostat treatment. 
Firsocostat in NASH patients led to decreasing ALT (101 U/L 
vs 57 U/L) and AST (62 IU/L to 46 IU/L) as well as decreased 
tissue inhibitor of metalloprotease 1 serum levels (275 ng/mL 
to 244 ng/mL).
A phase 2b clinical study targeted NASH patients with 
magnetic resonance imaging assessed hepatic steatosis by of 
>8% and liver stiffness of >2.5 kPa or NASH CRN score on liver 
biopsy consistent of F1-3. This trial evaluated 126 patients 
randomized to firsocostat 5 or 20 mg and placebo (2:2:1 
ratio). Firsocostat 20 mg, but not 5 mg reduced magnetic 
resonance imaging proton density fat fraction at week 12 
(−29% (20 mg) vs. −13% (5 mg) vs −8% (placebo)) [30]. 
Changes in liver stiffness measured by MRE did not differ 
among treatment groups. Unlike the phase 2a trial there was 
no statistically significant effect of drug treatment on liver 
biochemistry. Treatment was associated with clinically asymp-
tomatic hypertriglyceridemia (>500 mg/dL), observed in 14% 
of patients receiving 20 mg, 18% of patients receiving 5 mg, 
and none of the patients receiving placebo.
These efforts preceded a 48-week, Phase 2 (ATLAS study) 
evaluating key histological endpoints of three of the Gilead 
compounds in 392 patients with advanced fibrosis (F3-F4) due 
to NASH, while 56% had compensated cirrhosis. This rando-
mized, double-blind, placebo-controlled study evaluated the 
safety and efficacy of monotherapy and dual combination 
regimens of cilofexor 30 mg, firsocostat 20 mg and selonsertib 
18 mg. The selonsertib monotherapy treatment group was 
discontinued following termination of the STELLAR trials of 
selonsertib. No regimen led to a statistically significant 
increase in the proportion of patients who achieved the pri-
mary efficacy endpoint of a ≥ 1-stage improvement in fibrosis 
without worsening of NASH [31]. After 48 weeks, firsocostat 
(n = 33) and cilofexor (n = 34) each hit that goal in ~12% of 
patients. The combination selonsertib-firsocostat (n = 71) 
reached the endpoint in 15.5%, selonsertib-cilofexor (n = 68) 
in 19.1% and firsocostat-cilofexor (n = 67) in 20.9% of patients. 
The combination firsocostat-cilofexor improved multiple sec-
ondary endpoints compared with placebo, including 
a ≥ 2-point reduction in the NAS and ≥1-point reductions in 
steatosis, hepatocellular ballooning and lobular inflammation. 
In addition the combination led to statistically significant 
improvements of ALT, AST, bilirubin and ELF score, compared 
with placebo [29].
4.6. Cilofexor
Cilofexor (GS-9674) is a selective, nonsteroidal farnesoid 
X receptor (FXR) agonist. Cilofexor activates FXR in the intes-
tine and drives the physiologic release of FGF19, suppressing 
systemic FXR activation that causes dyslipidemia, pruritus, and 
hepatic injury. In a proof-of-concept study, 10 patients with 
NASH and F2–3 fibrosis who received 30 mg cilofexor once 
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daily for 12 weeks experienced decreased hepatic fat, liver 
stiffness, and improved liver biochemistry. This led to the 
design of a double-blind, placebo-controlled, phase 2 trial 
that examined 140 non-cirrhotic patients with NASH diag-
nosed by magnetic resonance imaging-proton density fat frac-
tion ≥8% and liver stiffness ≥2.5kPa by magnetic resonance 
elastography or historical liver biopsy were randomized to 
receive cilofexor 100 mg (n = 56), 30 mg (n = 56), or placebo 
(n = 28) orally once daily for 24 weeks [32]. At week 24, 
patients receiving cilofexor 100 mg had a median relative 
decrease in magnetic resonance imaging-proton density fat 
fraction of −22.7%, compared with an increase of 1.9% in 
placebo. Declines of large (≥30%) in magnetic resonance ima-
ging-proton density fat fraction was seen in 39% of patients 
on cilofexor 100 mg, 14% 14% of those receiving cilofexor 
30 mg and 13% on placebo. Cilofexor did not significantly 
affect liver biochemistry markers in any dosage compared to 
placebo, nor were markers of liver stiffness as assessed by 
magnetic resonance elastography, transient elastography, 
and serum markers affected by either regimen. Moderate to 
severe pruritus was more common in patients receiving cilo-
fexor 100 mg (14%) than in those receiving cilofexor 30 mg 
(4%) and placebo (4%). Cilofexor was part of the combos that 
were trialed in ATLAS study and that failed to meet with the 
primary endpoint.
4.7. BI1467335
BI1467335 (PXS-4728A) is an anti-inflammatory amine oxi-
dase copper-containing 3 (AOC3) inhibitor being developed 
to treat NASH. Boehringer Ingelheim acquired the com-
pound in 2015 to develop it for NASH. BI 1467335 acts by 
blocking leucocyte adhesion and tissue infiltration in inflam-
matory processes underlying NASH [33]. The clinical devel-
opment led to a phase 2a trial (NCT03166735) which was 
designed as a multi-center, double-blind enrolling 114 
patients with clinical evidence of NASH. The primary objec-
tives were to establish proof of clinical principle, investigate 
suitable dosing, and to evaluate the safety of BI 1467335. 
Patients have been randomized to either one of four 
dosages of BI 1467335 or to placebo for a 12-week treat-
ment period followed by a 4-week observation period. 
Primary outcome was decrease of plasma AOC3 activity 
after 12 weeks of treatment and BI 1467335 met with this 
target compared to placebo. The compound in this study 
was well-tolerated with no related serious adverse events. 
However, data from the preceding phase 1 study indicated 
risk for drug interactions of BI1467335, which led to the 
decision to discontinue clinical development by Boehringer 
Ingelheim and Pharmaxis [34].
4.8. Emricasan
Emricasan is an irreversible pan-caspase inhibitor that 
decreases serum aminotransferases and caspase activation in 
patients with NASH. A phase 2b double-blind, placebo- 
controlled study randomized 318 patients to emricasan 
(5 mg or 50 mg b.i.d.) or placebo for 72 weeks [35]. Patients 
had NASH CRN fibrosis stage F1-F3. This study postulated that 
72 weeks of emricasan treatment would improve liver fibrosis 
without worsening of NASH. In this trial, emricasan did not 
meet with the primary objective of fibrosis improvement with-
out worsening of NASH (emricasan 5 mg: 11.2%; emricasan 
50 mg: 12.3%; placebo: 19.0%).
A second phase 2b study sought to find a meaningful 
decrease in the hepatic venous pressure gradient in patients 
with NASH cirrhosis. To this end 263 patients with NASH 
cirrhosis and baseline hepatic venous pressure gradient 
exceeding 12 mmHg were randomized over 3 arms (twice 
daily oral emricasan 5 mg, 25 mg, 50 mg or placebo in 
a 1:1:1:1 ratio) for up to 48 weeks [36]. At 24 weeks a repeat 
hepatic venous pressure gradient measurement was per-
formed which served as the primary endpoint. There was no 
difference among arms in the primary endpoint even after 
adjusting for baseline hepatic venous pressure gradient, com-
pensation status, and nonselective beta-blocker use. Disease 
progression did not differ among groups.
4.9. Elafibranor
Elafibranor (GFT505) is a dual PPAR-α/δ agonist and attenuates 
glucose metabolism and insulin resistance and improves mar-
kers of dyslipidemia [37]. The compound was trialed in 
patients with combined dyslipidemia and/or insulin resistance 
and improvements in liver biochemistry (gGT, ALT, AP) were 
observed. These results suggested clinical efficacy and freed 
the way for the phase 2b, 52 weeks clinical trial which eval-
uated 2 dosages of elafibranor 80 mg (n = 93) or 120 mg 
(n = 89) doses compared to placebo (n = 89) in biopsy-proven 
NASH patients (NAS-score ≥3) without cirrhosis [38]. The pri-
mary outcome was resolution of NASH without worsening of 
fibrosis defined as complete absence of at least 1 out of 3 
NASH components; steatosis, ballooning or inflammation and 
without worsening of fibrosis to F3. A formal evaluation 
according to this endpoint, elafibranor did not lead to 
a resolution of NASH. However, at the time of study comple-
tion, recommendations on the definition of resolution of 
NASH had evolved to the current FDA/EMA accepted defini-
tions. In a post-hoc analysis using the updated endpoint more 
patients using elafibranor (120 mg) hit NASH resolution com-
pared to placebo (19% vs 12%, p = 0.045).This effect was more 
pronounced in patients with higher NAS-scores (NAS ≥4, 19% 
vs 9%, p = 0.013), in patients with fibrosis (NAS ≥4 and any 
fibrosis, 20% vs 11%, p = 0.009) and in patients with moderate 
to advanced fibrosis (NAS ≥4 and F2/F3 fibrosis, 13% vs 7%, 
p = 0.0001). The subsequent phase 3 RESOLVE-IT trial 
(NCT02704403) compared elafibranor 120 mg with placebo. 
The trial aimed to include 2000 patients with biopsy-proven 
NASH, but it increased minimal NAS-score for inclusion to ≥4 
(instead of ≥3) with a fibrosis score ≥1. The primary endpoint 
is the proportion of patients with resolution of NASH without 
worsening of fibrosis. After including more than 700 patients 
in the study, 19.2% of those treated with elafibranor met the 
compared to almost 15% of patients on placebo. After the 
disappointing interim results, Genfit terminated its effort to go 
for marketing authorization with elafibranor for this indica-
tion [39].
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4.10. JKB-121
JKB-121 is a weak antagonist of the TLR4 (toll-like receptor 4). 
TLR4 is a member of the toll-like receptor family and plays 
a role in pathogen recognition and activation of innate immu-
nity. Activation of the TLR4 leads to downstream activation of 
the NF-κB signaling pathway and production of pro- 
inflammatory cytokines. Lipopolysaccharide is the main ligand 
of TLR4, but several other lipids and lipopeptides have also 
been described as TLR-4 ligands. TLR4 activation also plays 
a role in insulin resistance and obesity-associated inflamma-
tion. In mice models nutritional fatty acids can activate TLR4 
while TLR4 knockout protects mice from obesity-associated 
insulin resistance and reduces liver steatosis and inflammation 
[40–42]. Liver and serum TLR4 concentration is increased in 
patients with NASH and correlated with liver stiffness mea-
sured by fibroscan [43,44]. Disrupting TLR4 activation could 
blunt the inflammatory response associated with liver steato-
sis. The only published human trial using JKB-121 was 
a randomized, double-blind, placebo controlled, phase II trial 
with three arms. Participants with biopsy-proven NASH with 
NAS ≥4 were randomized to either 5 mg twice daily JKB-121, 
10 mg twice daily JKB-121 or placebo. The primary outcome 
was a decrease of magnetic resonance imaging-derived pro-
ton density fat fraction (MRI-PDFF), with a range of secondary 
outcome measures, including liver function tests, lipid profile 
and BMI. A total of 65 patients were included in the study. 
After 24 weeks there was no significant difference between 
the treatment and placebo groups with regard to primary or 
secondary outcome [4]. Despite these disappointing results, 
a study with a similar compound, JKB-122, is currently ongoing 
to investigate whether it may induce histological NASH 
resolution.
5. What are the reasons for failure?
We describe 10 individual drugs coming from 10 drug classes 
with each distinctive and unique signatures and targets. This 
illustrates the multiple targets and the pleotropic pathways 
that are thought to be in play in NASH. One of the key 
questions for assessing new drug entities in the drug discov-
ery stage is whether there is adequate drug concentration and 
duration at the site of action (target) to elicit 
a pharmacological effect. The phase 2 trial with cilofexor 
illustrates this point as it provided only partial proof of FXR 
agonism. Cilofexor did not affect fasting plasma FGF19 levels, 
but reduced serum C4 levels, the metabolic intermediate for 
the synthesis of bile acids [32]. Most of the drugs that we 
describe failed to meet their efficacy standards in later stage 
trial. The development of AZD4076 (RG-125) was terminated 
at a very early (phase 1/2a) stage, and while solithromycin had 
entered testing in phase 2, one patient developed hepatotoxi-
city with ALAT > 3 ULN, a safety signal that was also seen 
during phase 1. This safety concern was independent of the 
indication NASH, as it was also seen in the development of the 
drug as an antibiotic compound. Four drugs were halted after 
the results of the phase 2 trials had become known. BI 
1467335 an amine oxidase copper-containing 3 (AOC3) inhi-
bitor had already entered phase 2a of clinical development, 
data from the preceding phase 1 study suggested the risk for 
drug interactions with BI1467335. The seladelpar studies were 
temporarily halted for almost 8 months because of suspicion 
that it caused interface hepatitis. The endpoint that was used 
to test the pan-caspase inhibitor emricasan differed from the 
other drugs. Almost all NASH compounds were tested against 
a wide panel of conventional endpoints (hepatic fibrosis) or 
liver biochemistry (liver enzymes) tests and wet or dry fibrosis 
assessments (direct fibrosis marker, elastography, fibroscan). 
By contrast, the efficacy of emricasan in the phase 2b program 
was evaluated by hepatic venous pressure gradient, and it 
failed to impact this endpoint. Four NASH drugs made it 
through to phase 3 clinical development, and three drugs 
(firsocostat, cilofexor, selonsertib) were part of Gilead’s 
STELLAR program. It is unfortunate that ~1700 patients were 
exposed to a combination of three drugs that failed to change 
the natural course of the disease. The STELLAR program has 
been criticized because of a lack of a well-designed placebo- 
controlled phase 2b study that would have informed the 
design of a larger phase 3 trial. There are several factors that 
may have contributed to the failure of the STELLAR phase 3 
program. Beyond the lack of an extensive placebo-controlled 
phase 2 study program [20], the efficacy estimation came from 
a phase 2 study that had sampled F2/3 NASH patients. 
Patients were randomized over 5 arms and were treated for 
24 weeks with 2 dosages selonsertib (6 or 18 mg), alone (2 
arms) and 2 arms combined with simtuzumab (125 mg), and 
simtuzumab alone (125 mg). A placebo arm was lacking. The 
proportion of patients with > 1 stage fibrosis reduction in both 
arms was comparable nor was there a statistical difference 
with that of the simtuzumab arm (n = 20). There was no 
dose response effect of selonsertib. So, in view of lack of 
robust efficacy parameters of firsocostat and selonsertib, the 
trial designers of the STELLAR program were sailing in 
uncharted waters. Cilofexor was the notable exception 
because this compound convincingly showed that it decreases 
hepatic fat on magnetic resonance imaging-proton density fat 
fraction, but not any of the other liver injury parameters seen 
in NASH. Cilofexor alone or in combination with firsocostat or 
selonsertib failed to meet the efficacy threshold. Despite these 
disappointments a number of trials that combine a number of 
therapeutic options are currently ongoing. Some trials primar-
ily focus on safety such as NCT02781584 which employs var-
ious combinations of selonsertib, firsocostat, cilofexor, 
fenofibrate and/or icosapent ethyl and NCT03517540 that 
uses the combination of tropifexor and cenicriviroc. Other 
combinations such that of tropifexor and licogliflozin is 
being trialed (NCT04065841) with the aim to see histological 
proof of improvement of NASH lesions.
The fourth compound in phase 3 that recently failed to 
demonstrate an effect at a preplanned interim analysis was 
elafibranor. Elafibranor was unable to meet with the FDA 
required endpoint ‘resolution of NASH without worsening of 
fibrosis’ that is required to receive accelerated approval. The 
phase 2 study had missed the same primary outcome, but 
a per protocol analysis that removed patients with baseline 
NAS< 4 and removal of low-recruiting centers detected an 
effect with the 120 mg dosage but not with 80 mg. This was 
probably the reason to include more advanced NASH patients 
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(NAS score ≥4, F1-3) in the phase 3 program, but that did not 
make a difference here at the time point of 18 months.
Importantly, current drug development programs in NASH 
aim to obtain conditional approval through analysis of 
a surrogate marker of clinical outcomes after 48 to 72 weeks. 
This is important to keep in mind when analyzing recent fail-
ures. The alternate approach – obtaining full approval by 
demonstrating an effects on liver-related outcomes or overall 
mortality – will require a much longer trial period, prolonging 
both exposure of patients to experimental drugs and increas-
ing costs.
6. What are the lessons?
6.1. Hard & intermediate endpoints
The ultimate goal of NASH treatment is to slow the progress 
of, halt, or reverse disease progression and improve clinical 
outcomes (prevent progression to cirrhosis and cirrhosis com-
plications, reduce the need for liver transplantation, and 
improve survival). While these are desired goals for treatment 
of our patients, they are at best impractical for drug develop-
ment. Clinical trials that would use these endpoints (liver- 
related morbidity and mortality) need to enroll a large sample 
size and expose patients for prolonged period of time to 
experimental drug. This is ethically challenging and a poor 
choice from an economical point of view. Thus, regulating 
authorities have come forward and defined intermediate bio-
markers such as biochemistry and imaging for phase 2 and 
liver histology for phase 3 trials as surrogate endpoints for 
conditional drug approvals. The choice of these surrogate 
endpoints has been developed thoroughly in a dialogue 
with academia and their choice is based on a link to clinical 
outcomes (‘hard endpoints’) such as liver-related morbidity 
and mortality. This regulatory approval framework has the 
strong advantage, that trials can be performed within 
a reasonably (short) timeframe [11]. In the path toward mar-
keting authorization, companies have to then still provide 
evidence on the benefit and risk of the compound under 
consideration during follow-up. This usually comes from 
a series of clinical trials and the drug must have successfully 
completed phase 1, phase 2, and phase 3 trials and post- 
approval (phase 4). In our view this holds a number of chal-
lenges that add to the reasons why so far no compounds have 
received full approval from marketing authorities.
6.2. Endpoints in phase 2 and 3 in clinical trials for 
fibrotic NASH
The explored endpoints vary between each phase of clinical 
trial development. Indeed, there is a clear disconnect between 
FDA required endpoints for early phase 2 trials compared to 
the larger formal phase 3 studies. The choice of these phase 2 
endpoints is among the reasons why a compound fails in 
phase 3 after being successfully trialed in phase 2. Early 
phase 2 trials are supported by noninvasive, disease-specific 
biomarkers, standard measures of liver injury (AST and ALAT), 
and noninvasive and imaging modalities that assess liver stiff-
ness or hepatic fat content [45]. The endpoints that are used in 
phase 3 are entirely histology based. The FDA stipulates that 
an endpoint should measure how a patient feels, functions, or 
survives. In the case of NASH, FDA has formulated three sets of 
endpoints for phase 3 trials based on change of lesions typical 
for NASH. Central to this endpoint is a (semi) quantitative 
evaluation of the liver biopsy using the NAS score for steatosis, 
ballooning, and steatohepatitis and NASH CRN score for fibro-
sis. The first endpoint states that there should be resolution of 
steatohepatitis defined as absent fatty liver disease or isolated 
or simple steatosis without steatohepatitis and a NAS score of 
0–1 for inflammation, 0 for ballooning, and any value for 
steatosis; without worsening of liver fibrosis on NASH CRN 
fibrosis score. The alternative endpoint includes improvement 
in liver fibrosis greater than or equal to one stage (NASH CRN 
fibrosis score) without worsening of steatohepatitis (defined as 
no increase in NAS for ballooning, inflammation, or steatosis). 
The final valid endpoint combines both items and includes 
both resolution of steatohepatitis and improvement in fibrosis 
using the specific scoring systems. Following this concept, 
successful drugs for NASH need to improve liver biochemistry, 
liver stiffness, or fat content but also to recover liver histology. 
This appears to be a tall order for the many drugs that have 
been trialed. Ursodeoxycholic acid is the most intuitive exam-
ple of a drug that potentially meets early phase 2 endpoints 
but fails in phase 3 [46]. This drug will improve liver transami-
nases in NASH patients, but consistently failed to improve liver 
histology in formal trials.
Going forward, additional evidence as to which of the 
above detailed phase 2 endpoints have the highest potential 
to predict drug response in phase 3 exploring liver histology 
will be required. To achieve this, international consortia 
(LITMUS and NIMBLE) have been founded through academia 
to define the best set of biomarkers and validate these accord-
ingly. In the end, a noninvasive surrogate endpoint for condi-
tional drug approval is the ultimate goal of these endeavors. 
Alternatively, an endpoint focusing on how a patient feels – 
measured through a validated health-related quality of life 
tool – could be one alternate way forward in NASH trials.
6.3. Liver histology
Liver histology is tightly linked to clinical outcome [14] and 
therefore the most relevant surrogate endpoint in the condi-
tional approval process. It is also a formidable hurdle. 
Although much desired, there are no approved compounds 
available that provide direct antifibrotic effect on stellate cells 
or on the extracellular matrix. The promise of some of the 
compounds in development is that they target upstream 
metabolic or inflammatory pathways that will drive downward 
reduction in fibrosis. Even if we have an effective antifibrotic 
compound available, it is unclear whether such a compound 
will show efficacy during the lifetime of a randomized clinical 
trial. Most phase 3 trials have a trial observation length of 
12–18 months.
While our picture of the pathophysiology of NASH has 
become more granular over the last years, the spaciotemporal 
dynamics of the three individual lesional components steato-
sis, hepatocellular inflammation, and fibrosis remains to be 
elucidated. Contrary to common belief that infers steady 
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progression, NASH is a highly heterogeneous and dynamic 
disease, and it is surprisingly hard to predict fibrosis progres-
sion. Published studies using paired biopsies have shown that 
while NASH may be progressive there is large variability 
among individuals. Higher baseline fibrosis stage portends 
a more rapid fibrosis progression but there are no other base-
line clinical, biochemical, and histological parameters that 
consistently predict future histological development. The cur-
rent concept supports a waxing and waning of disease activity 
[47] and it is unclear whether a compound is powerful enough 
to overcome the natural fluctuations of the disease within the 
limits of a relatively short trial time [48].
Lastly, there is a real and alarming issue with reporting of 
the biopsy slides of liver tissue. In an effort to estimate the 
diagnostic concordance among pathologists, digitized 678 
liver biopsies from 339 patients who participated in 
a randomized clinical trial examining an insulin sensitizer 
(MSDC-0602 K) in NASH were reassessed. The slides were 
read independently by three blinded expert hepatopatholo-
gists and the inter-reader linearly weighted kappas was lower 
than 0.61 for all of the components of the NASH CRN score. 
The authors concluded that current liver biopsy evaluation is 
suboptimal and went on to show that lack of reliability of 
endpoints and inclusion criteria greatly compromises the sta-
tistical power of any given study because of misclassifying 
fibrosis subgroups and attenuating apparent treatment 
effects [49]. While these data are alarming, it highlights the 
need to refine histology interpretation but should not misin-
terpreted as the need to abandon histology before a reliable 
noninvasive biomarker is defined and agreed on with regula-
tors [50]. We can shore up the quality of histological assess-
ment by [1] obtaining an adequately sized biopsy (>1.0 cm in 
length with >10 portal tracts) as this greatly reduces sampling 
error and [2] use of artificial intelligence assist systems for 
automated NASH biopsy evaluation. One in silico system 
(qFIBS) has been evaluated and found to reliably quantify 
fibrosis, lobular inflammation, ballooning, and steatosis. The 
technology is not well suited to establishing a new diagnosis 
but can be used as an adjunct quantitative tool to establish 
disease severity following the qualitative assessment by the 
pathologist [51].
6.4. Fast track
Many drugs under consideration for market authorization for 
NASH have been processed under the fast track ticket. FDA 
has created this process designed to facilitate the develop-
ment and expedite the review of drugs to treat serious con-
ditions and fill an unmet medical need. The prerequisite is that 
the compound much shows some advantage over available 
therapy, such as better efficacy with better outcome relative 
to comparators, while avoiding adverse events. For NASH the 
most pressing issue is that so far there is no drug available 
that is an answer to the emerging public health need and 
many applications will fall in this category. The advantage for 
companies is that they are offered intense guidance from FDA 
with frequent meetings with FDA to discuss the drug’s devel-
opment plan and ensure collection of appropriate data 
needed to support drug approval. While improved 
communication with regulatory agencies is key, so is carefully 
planning and design of the clinical drug development pro-
gram. If the STELLAR-3 and 4 phase 3 studies with selonsertib 
would have been successful, the lack of a placebo arm in the 
phase 2 studies would have been a footnote. Unfortunately, 
this has not been the case and this example shows that the 
even in the rush to the market the need for rigorous trial 
design is still there.
6.5. Natural history
Our understanding of the natural history of NASH is largely 
based on retrospective data coming from single centers. These 
research models have inherent confounders that are difficult 
to control. The sharp increase of number of clinical trials in this 
field has allowed an unbiased view of the natural history of 
NASH patients with histologically established fibrosis. While 
clinical trials cover only a short time span of the natural history 
of the disease and have limitations such as poor generaliz-
ability, they are valuable resources. The first data that have 
started to emerge show that NASH is a highly dynamic dis-
ease. A careful designed prospective cohort confirmed the 
dynamic nature of NASH. In a cohort of 446 patients followed 
over 4.9 years, steatohepatitis resolved in 29% of borderline 
NASH cases and in 22% of those with definite NASH [48]. 
Fibrosis progression by at least 1 stage occurred in 30%, but 
regression was seen in 34%. Patients with advanced fibrosis at 
baseline likely progress and this has led authors to introduce 
the 20% rule: 20% of patients with NASH with advanced (F3) 
fibrosis or compensated cirrhosis will progress to cirrhosis or 
develop decompensation, respectively, over a 2-year time 
period [52].
It is entirely possible that a randomized clinical trial is an 
inaccurate testing ground for NASH drugs. Phase 3 trials 
require a liver biopsy at baseline to confirm the NASH diag-
nosis, inflammatory activity or fibrosis stage. Currently patients 
are being categorized on basis of stage and grade of NASH, 
which is reasonable, but it is clear that the individual rates of 
disease progression vary greatly. This hampers drug develop-
ment because if a potential drug does not have a beneficial 
effect that trumps the natural variability of the disease it will 
fail in clinical trials. While it is possible that it possesses 
a (certain) beneficial effect in selected patients it does not 
have that on a population level. As such important informa-
tion is lost as aggregate clinical trials results fail to unmask the 
effect beyond the signal-to-noise ratio but may offer us impor-
tant lessons on the contribution of pathophysiological path-
ways. Careful stratification of patients by predicted outcome 
would benefit clinical trial design. Importantly, predictors of 
‘rapid progression’ could identify the subgroup of patients 
with the greatest need for pharmacological treatment and 
enrich a trial with patients that are responsive to the specific 
mechanism of action of the trialed drug.
Most of the studies in the field focus on patients with 
advanced liver disease with liver fibrosis > F2/3. The selection 
of these patients for clinical trials is difficult, because noninva-
sive markers or elastography are incomplete predictors of the 
fibrosis stage [45]. As a result many NASH patients are filtered 
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out in this process. These patients included in the NASH trials 
represent the extreme end of NASH and are only a fraction of 
the NASH patients who seek daily clinical care. Histological 
information is responsible for ~60% of all screen fails. 
Funneling highly selected patients through the rigid structure 
of a randomized clinical trial and reducing NASH to semi- 
quantifiable histological lesions probably oversimplifies 
NASH. The use of difficult to satisfy inclusion criteria clearly 
threatens the external validity of the trial results. Also, the 
static nature of histology does not allow to assess the speed 
at which the patient has developed to this disease stage – 
highlighting again, that dynamic markers of inflammation and 
fibrosis could be very useful to define a study population.
6.6. Placebo response
Another aspect of NASH drug development is the placebo 
response. Data from the STELLAR and REGENERATE studies 
illustrate that an expected placebo response for >1 stage 
improvement in fibrosis without NASH worsening lies 
between 10% and 14% [15,19]. The current standard-of-care 
for NASH is adaptation of lifestyle focused on adopting 
improved nutrient intake and engage in regular exercise 
with a focus on losing weight and improve insulin sensitivity 
amongst others. When executed and leading to a loss of 
7–10% of baseline weight this strategy is associated with 
improvements of histological components of NASH in some 
patients [53]. Inclusion in a clinical trial may heighten the 
awareness of the need for lifestyle modification and the pro-
portion of (successfully) adherent patients might be distribu-
ted unevenly over the arms skewing the result of the trial. That 
is why the ‘Liver Forum Standard of Care Working Group’ has 
recommended to trial designers to evaluate at screening for 
diet and exercise habits, check for prior life-style stability and 
counsel and document changes in diet and physical activity 
throughout the trial [54].
7. Conclusion
Drug development in fibrotic NASH has been a difficult task. 
However, with an improving understanding of the disease 
processes, the enhancement of technologies that support 
the development of novel, dynamic surrogate endpoints and 
the relevant clinical subgroups, eventually, drug candidates 
will emerge. This will allow the much needed provision of 
adequate care for the increasing number of patients reaching 
end-stage liver disease from NASH. The rush to position a drug 
with conditional approval has led to some temporary failures, 
but these disappointments have not stopped the tremendous 
academic efforts that will support drug-developers in their 
quest to provide effective and safe drugs for NASH.
8. Expert opinion
There is no doubt that NASH represents a formidable drug 
market [55]. NASH is highly prevalent and associated with the 
metabolic syndrome. Lifestyle interventions while successful 
are difficult to maintain in the overall majority of patients. The 
failure to effectively implement and execute lifestyle changes 
has encouraged the development of pharmaceutical alterna-
tives. The pharmaceutical industry has responded to this 
emerging need by accelerating efforts to bring drugs to the 
market [56].
While there is a steep increase of the number of clinical 
trials devoted to NASH, none of the drugs in the pipeline for 
NASH has made it to the market. One of the major issues that 
looms over the field is the concept of heterogeneity. The 
complexity of its pathophysiology is reflected by the multi-
tude of pharmacological targets in development. Results from 
interventional trials are difficult to compare due to inconsis-
tent definitions of relevant disease parameters. The popula-
tions included in these trials are heterogeneous with respect 
to the contribution of underlying obesity, type 2 diabetes, and 
other comorbidities and the treatments provided for these 
comorbidities [57].
We have outlined the failure of many drugs in NASH drug 
development. The compounds that have failed in clinical 
trials target a number of different pathways. It is difficult to 
judge from these data sets whether the negative results are 
due to use of ineffective drugs or to the fact that the 
targeted pathways are irrelevant for the pathogenesis. 
Probably, optimization of therapeutic outcomes for NASH 
may be best realized by targeting multiple pathogenic path-
ways rather than modulating a single pathway. As the qua-
litative and quantitative contribution of the individual 
pathways to the multiple disease processes in NASH is 
unknown, it has been proven difficult to push the door 
open. The recent effort to clarify the nomenclature by intro-
ducing a comprehensive set of criteria (including grade of 
activity and stage of fibrosis) for the diagnosis of MAFLD are 
helpful [58].
The hunt for an effective drug through the formal phases of 
regulatory drug development is rigorous and costly and 
indeed it is possible that the string of failures will shy away 
researchers and clinical trialists from the field. There is the 
need to rethink the concept of the clinical trial with the 
current (histological) endpoints for NASH [59]60. While it is 
clear that the therapeutic targeting of NASH is a hard nut to 
crack, we are convinced that eventually our efforts will bear 
fruit. In the short term the clinical trials (successful or not) will 
offer us better understanding of the natural history and 
a granular picture of the effectors relevant to the disease. In 
the long run better patient selection with a forward view on 
precision management, guided by use of accurate biomarkers 
and use of a multifaceted approach will be needed to discover 
the drugs that are most likely are able to alter the natural 
history of NASH.
Despite the obvious disappointment with clinical trials, these 
endeavors have also shed much light on the pathogenesis of 
NASH and we are cautiously optimistic that effective therapies 
will be identified in the next years. Achieving this will require 
continued refinement of clinical trial endpoints, continued 
engagement of trial sponsors and regulatory authorities, and 
continued participation of dedicated patients in clinical trials.
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